Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2015

View Archived Issues

Synaptic activity studied in HSA21-encoded miRNAs

Data correlates CACNA1B mutation with myoclonus dystonia syndrome

PRMT5 revealed as a potential biomarker of CLL progression and transformation

Nestle invests in microbiome therapeutics firm Seres Health

Tivorsan develops pilot manufacturing process for TVN-102, triggering milestone payments

Phase I trial results shows potential for GR-MD-02 in NASH patients with fibrosis

Ultragenyx begins new program for KRN-23 in tumor-induced osteomalacia

Arena Pharmaceuticals reports data from phase Ib trial of APD-334

ExterNautics reports discovery of anti-FAT1 MAbs

Sanofi discloses new TAFIa inhibitors

Gilead Sciences presents novel PI3Kdelta inhibitors

Kala Pharmaceuticals patents new VEGFR-2 inhibitors

China investigators divulge NEP inhibitor prodrugs

MerLion Pharmaceuticals reports phase II data for finafloxacin in urinary tract infections

Promising results presented for novel complement inhibitors

FDA grants orphan drug status to ATR-101 for Cushing's syndrome

FDA grants fast track designation to Debio-1450 for ABSSSI

Transgenic Ebola vaccine set to enter phase I trials in China

Boehringer Ingelheim and BioMed X to discover new epigenetic regulators of COPD

Intellia Therapeutics and Novartis collaborate on CRISPR/Cas9-based therapies

Stemline Therapeutics licenses novel reversible inhibitor of XPO1 from CanBas

Melinta's delafloxacin meets primary endpoint in phase III ABSSSI study

FDA approves Rytary extended-release capsules for Parkinson's disease

Conatus announces pharmacokinetic data in support of emricasan development

FDA approves Savaysa for prevention of embolism and stroke in non-valvular atrial fibrillation

FDA advisory committee recommends approval of Sandoz biosimilar filgrastim

Advanced Accelerator Applications acquires Atreus and starts phase I/II trial of imaging agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...